August 2017 Surety Medicine Teleconference:
Key Stakeholders in the Army Substance Abuse Program
-- Developing an Alliance with the Competent Medical
WEDNESDAY, 16 August 2017 will bring the next Surety Medicine Teleconference, at 1 pm (1300 hrs) Eastern Time. The topic for August will be “Key Stakeholders in the Army Substance Abuse Program -- Developing an Alliance with the Competent Medical Authority.” The presenter is a civilian Army Senior Employee Assistance Professional who serves as an Army Substance Abuse Program Manager and Alcohol and Drug Control Officer.
To receive access information for attending the presentation by dial-in audio or on your computer via Defense Collaboration Services (DCS), send an email request to:
SCHEDULE OF SURETY MEDICINE TELECONFERENCES FOR FY 2017
20 SEP 2017
Abuse, Dependence, and Substance Use Disorders: DSM-IV-TR vs. DSM-5
ALERT: FDA Simplifies Rule for Anthrax PEP
FDA APPROVES ANTHRAX VACCINE FOR POST-EXPOSURE PROPHYLAXIS
The US Food and Drug Administration (FDA) has approved the current Anthrax Vaccine Adsorbed for use in combination with antibiotic therapy after a confirmed or suspected exposure to Bacillus anthracis, the causative agent for anthrax. The vaccine had been approved in 1970 for pre-exposure protection of those who might be exposed to the organism, but this recent approval for use in post-exposure prophylaxis (PEP) approves the use of the vaccine in combination with selected antibiotics to significantly improve the chances of survival in patients exposed to inhaled anthrax, without the previously required use of an investigational new drug (IND) protocol.
Additional information is available from the FDA at:
ALERT: Autoinjector Shelf Life Extension Program: UPDATED JULY 5, 2017
NERVE AGENT ANTIDOTE SHELF LIFE EXTENSION PROGRAM: Many expiration date extensions for autoinjector medications expire in 2017!
Check any auto-injector medication stores you have. Select the link
below for additional information from the FDA.
The US Food and Drug Administration (FDA) is alerting health care professionals and emergency responders that specific lots of DuoDote combined nerve agent antidote auto-injectors have been approved for shelf life extensions beyond labelled expiration dates, some are now extended out to 2022. Complete FDA information related to the auto-injector shelf life extension program can be found at: http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm .
Information on this page also includes the latest updates (4/15/2016) on shelf life
extensions for the AtroPen (atropine), CANA (diazepam), morphine sulfate, and
pralidoxime chloride auto-injectors.